RMS CV% | SD (mm2) | Mean difference (mm2) | |||||||||||
MT | cMF | LT | cLF | MT | cMF | LT | cLF | MT | cMF | LT | cLF | ||
ALL | n = 158 | 1.1 | 1.4 | 1.2 | 1.1 | 16.0 | 10.6 | 15.2 | 9.0 | 4.4* | 1.5 | 3.1* | 1.6* |
KLG 0 | n = 97 | 0.9 | 1.3 | 1.1 | 1.1 | 13.8 | 9.7 | 14.8 | 8.8 | 3.8 | 2.1 | 2.8 | 2.1 |
KLG 2 | n = 31 | 1.1 | 1.6 | 1.0 | 1.1 | 17.7 | 12.5 | 11.9 | 8.9 | 1.0 | 1.9 | 6.3 | 1.0 |
KLG 3 | n = 30 | 1.4 | 1.4 | 1.4 | 1.2 | 19.8 | 11.5 | 19.0 | 10.1 | 10.0 | −1.0 | 0.8 | 0.3 |
AZ GE LB | n = 19 | 0.8 | 1.3 | 0.7 | 0.9 | 11.4 | 9.9 | 8.3 | 7.2 | 3.4 | −0.8 | −3.1 | 0.7 |
SF GE LB | n = 15 | 1.2 | 1.7 | 1.4 | 1.0 | 18.7 | 11.5 | 17.8 | 7.9 | 1.1 | −4.4 | −2.2 | −0.4 |
BO GE SB | n = 26 | 1.1 | 1.2 | 1.1 | 1.2 | 14.8 | 8.8 | 15.3 | 9.7 | 9.3 | 3.3 | 2.2 | 3.2 |
NW GE SB | n = 25 | 1.0 | 1.3 | 1.2 | 1.5 | 16.3 | 10.6 | 15.5 | 12.7 | 3.7 | 0.9 | 6.7 | −1.1 |
DU SI Trio | n = 30 | 0.9 | 1.5 | 1.2 | 0.9 | 14.8 | 11.9 | 15.4 | 6.8 | 1.0 | 1.3 | 2.9 | 3.2 |
UT SI Trio | n = 15 | 1.0 | 1.1 | 1.0 | 1.1 | 15.6 | 8.7 | 14.2 | 9.7 | −5.3 | 2.0 | 1.5 | 1.5 |
IN SI Trio | n = 28 | 1.3 | 1.6 | 1.3 | 1.0 | 16.4 | 11.1 | 15.9 | 7.9 | 11.9 | 4.8 | 8.8 | 2.2 |
*Mean difference significantly different from 0 at p<0.05 (t test). Mixed effect models did not indicate significant differences (in mean differences) between KLGs and only borderline significance between imaging sites; therefore the t test were not applied to these subgroups. The mean tAB values in the cohort (n = 158) were 1106 mm2 for MT, 538 mm2 for cMF, 939 mm2 for LT and 583 mm2 for cLF. Sites were: AZ, Arizona; SF, San Francisco; BO, Boston; NW, Northwestern; DU, Durham; UT, Utah; IN, Indiana. Manufacturers were: GE, GE Healthcare; SI, Siemens (Trio).
cLF, central lateral femoral condyle; cMF, central medial femoral condyle; LB, long bore magnet; LT, lateral tibia; MT, medial tibia; RMS CV%, root mean square coefficient of variation; SB, short bore magnet.